fluoxetine has been researched along with Chronic Insomnia in 50 studies
Fluoxetine: The first highly specific serotonin uptake inhibitor. It is used as an antidepressant and often has a more acceptable side-effects profile than traditional antidepressants.
fluoxetine : A racemate comprising equimolar amounts of (R)- and (S)-fluoxetine. A selective serotonin reuptake inhibitor (SSRI), it is used (generally as the hydrochloride salt) for the treatment of depression (and the depressive phase of bipolar disorder), bullimia nervosa, and obsessive-compulsive disorder.
N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine : An aromatic ether consisting of 4-trifluoromethylphenol in which the hydrogen of the phenolic hydroxy group is replaced by a 3-(methylamino)-1-phenylpropyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "An international, multicentre, double blind parallel group study compared the tolerability and efficacy of moclobemide with the selective serotonin reuptake inhibitor (SSRI) fluoxetine for panic disorder." | 9.09 | Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. ( Behnke, K; Bouwer, C; Tiller, JW, 1999) |
| "This paper reports combined results of three identical, multisite, randomized, double-blind, 8-week, acute-phase trials comparing nefazodone (n = 64) with fluoxetine (n = 61) in outpatients with nonpsychotic major depressive disorder and insomnia." | 9.08 | Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. ( Albala, BJ; Armitage, R; Erman, MK; Fleming, JB; Gillin, JC; Kaplita, SB; McQuade, RD; Moldofsky, H; Montplaisir, J; Rush, AJ; Vogel, GW; Winokur, A; Yonkers, KA, 1998) |
| "This retrospective chart review examined the relative effectiveness of fluoxetine and trazodone in relieving insomnia associated with depressive disorders in adolescents (aged 13-17 years)." | 7.69 | Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders. ( Bhatara, VS; Fogas, BS; Kallepalli, BR; Misra, LK; Tervo, RC, 1997) |
| " The rate of recurrence of the fluoxetine-associated adverse events was low, with headache (3 [27%] of 11 cases), nausea (2 [22%] of 9 cases), and decreased libido (5 [18%] of 28 cases) being the most common." | 5.10 | Citalopram treatment of fluoxetine-intolerant depressed patients. ( Calabrese, JR; Londborg, PD; Shelton, MD; Thase, ME, 2003) |
| "Common adverse events associated with initiating fluoxetine treatment in depressed patients, including nausea, insomnia, nervousness, and somnolence, resolve in the majority of patients and become significantly less frequent with continued treatment over a 6-month period." | 5.09 | Changes in adverse events reported by patients during 6 months of fluoxetine therapy. ( Amsterdam, JD; Beasley, CM; Michelson, D; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Sundell, KL; Tamura, RN; Zajecka, J, 1999) |
| "An international, multicentre, double blind parallel group study compared the tolerability and efficacy of moclobemide with the selective serotonin reuptake inhibitor (SSRI) fluoxetine for panic disorder." | 5.09 | Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. ( Behnke, K; Bouwer, C; Tiller, JW, 1999) |
| "Differences between the side effect profiles of clomipramine (CMI) and the selective serotonin reuptake inhibitors may be important factors in both treatment outcome and patient selection in obsessive-compulsive disorder (OCD)." | 5.09 | Side effects as predictors of drug response in obsessive-compulsive disorder. ( Ackerman, DL; Bystritsky, A; Greenland, S, 1999) |
| "This paper reports combined results of three identical, multisite, randomized, double-blind, 8-week, acute-phase trials comparing nefazodone (n = 64) with fluoxetine (n = 61) in outpatients with nonpsychotic major depressive disorder and insomnia." | 5.08 | Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder. ( Albala, BJ; Armitage, R; Erman, MK; Fleming, JB; Gillin, JC; Kaplita, SB; McQuade, RD; Moldofsky, H; Montplaisir, J; Rush, AJ; Vogel, GW; Winokur, A; Yonkers, KA, 1998) |
| " For individual adverse events that developed or worsened during therapy, more fluoxetine-treated patients reported rhinitis and tremor (p less than or equal to ." | 5.07 | Fluoxetine versus trazodone: efficacy and activating-sedating effects. ( Beasley, CM; Bosomworth, JC; Dornseif, BE; Pultz, JA; Sayler, ME, 1991) |
| " To assess rates and temporal patterns of activation and sedation as well as dose-effect relationships, adverse event data were evaluated from a fixed-dose study comparing placebo and fluoxetine 5, 20, and 40 mg/day in the treatment of major depressive disorder (N = 363) and two fixed-dose studies pooled together comparing placebo and fluoxetine 20, 40, and 60 mg/day in the treatment of major depressive disorder (N = 746)." | 5.07 | Fluoxetine: activating and sedating effects at multiple fixed doses. ( Beasley, CM; Potvin, JH; Sayler, ME; Weiss, AM, 1992) |
| "The side effect profile and safety of fluoxetine are reviewed." | 3.75 | The side effect profile and safety of fluoxetine. ( Wernicke, JF, 1985) |
| "This retrospective chart review examined the relative effectiveness of fluoxetine and trazodone in relieving insomnia associated with depressive disorders in adolescents (aged 13-17 years)." | 3.69 | Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders. ( Bhatara, VS; Fogas, BS; Kallepalli, BR; Misra, LK; Tervo, RC, 1997) |
| "Most adults with Major Depressive Disorder (MDD) will not experience a remission with the first antidepressant trial." | 2.80 | A rest-activity biomarker to predict response to SSRIs in major depressive disorder. ( McCall, WV, 2015) |
| "There are limited data on the impact of insomnia in response to acute treatment, which is particularly relevant with serotonin-selective reuptake inhibitors, given their tendency to worsen sleep architecture." | 2.77 | Insomnia moderates outcome of serotonin-selective reuptake inhibitor treatment in depressed youth. ( Croarkin, P; Emslie, GJ; Hughes, C; Kennard, BD; Mayes, TL; Nakonezny, PA; Tao, R; Zhu, L, 2012) |
| "Significant improvements in insomnia were observed for eszopiclone cotherapy relative to placebo cotherapy (mean change from baseline on the ISI: -11." | 2.76 | A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. ( Fava, M; Huang, H; Iosifescu, DV; Mischoulon, D; Schaefer, K; Wessel, TC; Wilson, A, 2011) |
| "Sixty adults with both depression and insomnia symptoms, who were free of significant primary sleep disorders, received open-label fluoxetine for 9weeks." | 2.76 | Dissection of the factors driving the placebo effect in hypnotic treatment of depressed insomniacs. ( Blocker, J; Boggs, N; D'Agostino, R; Kimball, J; Lasater, B; McCall, WV; Rosenquist, PB, 2011) |
| "Insomnia has been linked to suicidal ideas and suicide death in cross-sectional and longitudinal population-based studies." | 2.75 | Insomnia severity is an indicator of suicidal ideation during a depression clinical trial. ( Blocker, JN; Boggs, N; D'Agostino, R; Kimball, J; Lasater, B; McCall, WV; Rosenquist, PB, 2010) |
| "Insomnia is associated with poor health related quality of life (HRQOL) in depressed patients." | 2.75 | Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression. ( Blocker, JN; Boggs, N; D'Agostino, R; Haskett, R; Kimball, J; Krystal, A; Lasater, B; McCall, WV; McDonald, WM; Rosenquist, PB, 2010) |
| "Insomnia and major depressive disorder (MDD) may coexist." | 2.73 | Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression. ( Caron, J; Fava, M; Krystal, A; McCall, WV; Roth, T; Rubens, R; Wessel, T; Wilson, P, 2007) |
| "Reboxetine is a novel selective noradrenaline reuptake inhibitor." | 2.71 | Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression. ( Held, K; Kuenzel, HE; Murck, H; Steiger, A; Ziegenbein, M, 2004) |
| "Patients (N = 284) with DSM-IV major depressive disorder were randomly assigned in a double-blind fashion to fluoxetine, paroxetine, or sertraline for 10 to 16 weeks of treatment." | 2.70 | Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia. ( Fava, M; Gonzales, JS; Hoog, SL; Judge, RA; Kopp, JB; Nilsson, ME, 2002) |
| "Cotherapy was effective in reducing insomnia but not anxiety or core symptoms (low mood, suicidality, reduced interest)." | 2.70 | Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression? ( Glaudin, V; Londborg, PD; Painter, JR; Smith, WT, 2002) |
| "Rates of improvement in insomnia (HAM-D insomnia items), agitation (HAM-D agitation item), and anxiety (SCL anxiety subscale) were essentially identical in the two treatment groups." | 2.69 | Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine. ( Grothaus, L; Heiligenstein, JH; Katon, W; Revicki, D; Simon, GE, 1998) |
| " Discontinuation for lack of efficacy was lower in BP II (5%) than in UP (12%) patients (p = not significant [NS]), whereas dropouts for adverse events were similar in BP II (11%) and UP (9%) patients." | 2.69 | Efficacy and safety of fluoxetine in treating bipolar II major depressive episode. ( Amsterdam, JD; Beasley, C; Fawcett, J; Garcia-España, F; Quitkin, FM; Reimherr, FW; Rosenbaum, JF; Schweizer, E, 1998) |
| " There were 188 adverse events: insomnia, dizziness, headache, nausea, dry mouth and myoclonic jerks were the most common." | 2.68 | Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients. ( Hawley, CJ; McPhee, S; Pattinson, HA; Quick, SJ; Ratnam, S, 1996) |
| "Fluoxetine is an efficacious, nonsedative antidepressant, but its selective efficacy on symptoms of insomnia has not been thoroughly explored." | 2.68 | The effects of fluoxetine on symptoms of insomnia in depressed patients. ( Faries, D; Satterlee, WG, 1995) |
| "Trazodone is an effective hypnotic for patients with antidepressant-associated insomnia." | 2.67 | Trazodone for antidepressant-associated insomnia. ( Adler, LA; Nierenberg, AA; Peselow, E; Rosenthal, M; Zornberg, G, 1994) |
| "Fluoxetine was well tolerated during both 24-week continuation periods." | 2.67 | Continuation treatment of OCD: double-blind and open-label experience with fluoxetine. ( Birkett, M; Genduso, L; Koran, L; Tollefson, GD, 1994) |
| "or fluoxetine p." | 2.67 | Efficacy and safety of morning versus evening fluoxetine administration. ( Beasley, CM; Bosomworth, JC; Usher, RW, 1991) |
| "Insomnia disorder is a subjective condition of unsatisfactory sleep (e." | 2.58 | Antidepressants for insomnia in adults. ( Baldwin, DS; Everitt, H; Lipinska, G; Malizia, AL; Manson, CC; Mayers, A; Stuart, B; Wilson, S, 2018) |
| "Several adverse events (insomnia, asthenia, somnolence, gastroenteritis, decreased libido, chills, and confusion) occurred significantly more frequently among fluoxetine-treated patients." | 2.41 | Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose. ( Beasley, CM; Gonzales, JS; Koke, SC; Nilsson, ME, 2000) |
| "Insomnia is a particularly frequent complaint, and it is reported by more than 90% of depressed patients." | 2.40 | Antidepressant treatment of the depressed patient with insomnia. ( Thase, ME, 1999) |
| "Clinical benefits include reduced insomnia in those depressed and/or on antidepressants." | 1.34 | Does trazodone have a role in palliating symptoms? ( Davis, MP, 2007) |
| " Treatment-emergent adverse effects were assessed at each study visit." | 1.32 | Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. ( Fava, M; Lamon-Fava, S; Lin, KM; Mischoulon, D; Perlis, RH; Rosenbaum, JF; Smoller, JW; Wan, YJ, 2003) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (8.00) | 18.7374 |
| 1990's | 21 (42.00) | 18.2507 |
| 2000's | 16 (32.00) | 29.6817 |
| 2010's | 9 (18.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Everitt, H | 1 |
| Baldwin, DS | 1 |
| Stuart, B | 1 |
| Lipinska, G | 1 |
| Mayers, A | 1 |
| Malizia, AL | 1 |
| Manson, CC | 1 |
| Wilson, S | 1 |
| McCall, WV | 8 |
| Cawkwell, P | 1 |
| Lawler, A | 1 |
| Maneta, E | 1 |
| Coffey, BJ | 1 |
| Blocker, JN | 2 |
| D'Agostino, R | 3 |
| Kimball, J | 3 |
| Boggs, N | 3 |
| Lasater, B | 3 |
| Rosenquist, PB | 3 |
| Haskett, R | 1 |
| Krystal, A | 3 |
| McDonald, WM | 1 |
| Fava, M | 6 |
| Schaefer, K | 1 |
| Huang, H | 1 |
| Wilson, A | 1 |
| Iosifescu, DV | 1 |
| Mischoulon, D | 2 |
| Wessel, TC | 1 |
| Blocker, J | 1 |
| Emslie, GJ | 1 |
| Kennard, BD | 1 |
| Mayes, TL | 1 |
| Nakonezny, PA | 1 |
| Zhu, L | 1 |
| Tao, R | 1 |
| Hughes, C | 1 |
| Croarkin, P | 1 |
| McCall, C | 1 |
| Smith, WT | 1 |
| Londborg, PD | 2 |
| Glaudin, V | 1 |
| Painter, JR | 1 |
| Calabrese, JR | 1 |
| Shelton, MD | 1 |
| Thase, ME | 2 |
| Perlis, RH | 1 |
| Smoller, JW | 1 |
| Wan, YJ | 1 |
| Lamon-Fava, S | 1 |
| Lin, KM | 1 |
| Rosenbaum, JF | 4 |
| Winokur, A | 2 |
| DeMartinis, NA | 1 |
| McNally, DP | 1 |
| Gary, EM | 1 |
| Cormier, JL | 1 |
| Gary, KA | 1 |
| Lawrence, RW | 1 |
| Kuenzel, HE | 1 |
| Murck, H | 1 |
| Held, K | 1 |
| Ziegenbein, M | 1 |
| Steiger, A | 1 |
| Poryazova, R | 1 |
| Siccoli, M | 1 |
| Werth, E | 1 |
| Bassetti, CL | 1 |
| Wessel, T | 2 |
| Rubens, R | 2 |
| Caron, J | 2 |
| Amato, D | 1 |
| Roth, T | 2 |
| Csoka, AB | 1 |
| Shipko, S | 1 |
| Davis, MP | 1 |
| Prospero-Garcia, KA | 1 |
| Torres-Ruiz, A | 1 |
| Ramirez-Bermudez, J | 1 |
| Velazquez-Moctezuma, J | 1 |
| Arana-Lechuga, Y | 1 |
| Teran-Perez, G | 1 |
| Wilson, P | 1 |
| Parish, JM | 1 |
| Worthington, J | 1 |
| Davidson, K | 1 |
| Alpert, J | 1 |
| Nierenberg, AA | 2 |
| Satterlee, WG | 1 |
| Faries, D | 1 |
| Tollefson, GD | 1 |
| Birkett, M | 1 |
| Koran, L | 1 |
| Genduso, L | 1 |
| Adler, LA | 1 |
| Peselow, E | 1 |
| Zornberg, G | 1 |
| Rosenthal, M | 1 |
| Hawley, CJ | 1 |
| Quick, SJ | 1 |
| Ratnam, S | 1 |
| Pattinson, HA | 1 |
| McPhee, S | 1 |
| deVries, MW | 1 |
| Peeters, FP | 1 |
| Zajecka, J | 2 |
| Tracy, KA | 1 |
| Mitchell, S | 1 |
| Freeman, SA | 1 |
| Kallepalli, BR | 1 |
| Bhatara, VS | 1 |
| Fogas, BS | 1 |
| Tervo, RC | 1 |
| Misra, LK | 1 |
| Simon, GE | 1 |
| Heiligenstein, JH | 1 |
| Grothaus, L | 1 |
| Katon, W | 1 |
| Revicki, D | 1 |
| Rush, AJ | 1 |
| Armitage, R | 1 |
| Gillin, JC | 1 |
| Yonkers, KA | 1 |
| Moldofsky, H | 1 |
| Vogel, GW | 1 |
| Kaplita, SB | 1 |
| Fleming, JB | 1 |
| Montplaisir, J | 1 |
| Erman, MK | 1 |
| Albala, BJ | 1 |
| McQuade, RD | 1 |
| Amsterdam, JD | 2 |
| Garcia-España, F | 1 |
| Fawcett, J | 1 |
| Quitkin, FM | 2 |
| Reimherr, FW | 2 |
| Schweizer, E | 1 |
| Beasley, C | 1 |
| Tiller, JW | 1 |
| Bouwer, C | 1 |
| Behnke, K | 1 |
| Tamura, RN | 1 |
| Sundell, KL | 1 |
| Michelson, D | 1 |
| Beasley, CM | 5 |
| Ackerman, DL | 1 |
| Greenland, S | 1 |
| Bystritsky, A | 1 |
| Nilsson, ME | 2 |
| Koke, SC | 1 |
| Gonzales, JS | 2 |
| Hoog, SL | 1 |
| Judge, RA | 1 |
| Kopp, JB | 1 |
| Sayler, ME | 2 |
| Weiss, AM | 1 |
| Potvin, JH | 1 |
| Usher, RW | 1 |
| Bosomworth, JC | 2 |
| Keck, PE | 1 |
| Hudson, JI | 1 |
| Dorsey, CM | 1 |
| Campbell, PI | 1 |
| Dornseif, BE | 1 |
| Pultz, JA | 1 |
| Metz, A | 1 |
| Shader, RI | 1 |
| Altamura, AC | 1 |
| Montgomery, SA | 1 |
| Wernicke, JF | 2 |
| Cohn, JB | 1 |
| Wilcox, C | 1 |
| Stark, P | 1 |
| Hardison, CD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Hypnotics in the Treatment of Psychiatric Disorders[NCT00247624] | Phase 4 | 60 participants (Actual) | Interventional | 2005-10-31 | Completed | ||
| The Efficacy of Eszopiclone 3 mg as Adjunctive Therapy in Subjects With Insomnia Related to Generalized Anxiety Disorder.[NCT00235508] | Phase 4 | 420 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Depression Response to Eszopiclone in Adults With Major Depressive Disorder (DREAMDD): A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, 8-Week, Safety & Efficacy Study of Eszopiclone 3 mg Compared to Placebo in Subjects With Insomnia Relate[NCT00368030] | Phase 3 | 545 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| An Investigation of the Antidepressant Efficacy of a Dopamine Agonist With Neurotrophic Properties in Bipolar Disorder[NCT00025792] | Phase 2 | 200 participants | Interventional | 2001-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"The BASIS 32 psychometric includes several subscales, including daily living and role functioning (DLRF). These subscales are rated from 0-4, with higher scores indicating a greater deal of difficulty in this dimension and lower scores denoting better outcomes. Measured weekly for 9 weeks. Reported as mean of 9 weeks." (NCT00247624)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine (FLX) Plus Eszopiclone (ESZ) | 0.81 |
| FLX Plus Placebo | 1.2 |
The Insomnia Severity Index has seven questions. The seven answers are added up to get a total score, range 0-28. Lower scores represent better outcomes. Total score categories: 0-7 = No clinically significant insomnia, 8-14 = Subthreshold insomnia, 15-21 = Clinical insomnia (moderate severity), 22-28 = Clinical insomnia (severe). (NCT00247624)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine (FLX) Plus Eszopiclone (ESZ) | 21.1 |
| FLX Plus Placebo | 20.2 |
The Q-LES-Q is scored from 0-100, with higher scores better than lower. Measured weekly for 9 weeks. Reported as mean of 9 weeks. (NCT00247624)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine (FLX) Plus Eszopiclone (ESZ) | 50.2 |
| FLX Plus Placebo | 46.9 |
"The BASIS 32 psychometric includes several subscales, including relation to self and others (RSO). These subscales are rated from 0-4, with higher scores indicating a greater deal of difficulty in this dimension. Measured weekly for 9 weeks. Reported as mean of 9 weeks." (NCT00247624)
Timeframe: 9 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Fluoxetine (FLX) Plus Eszopiclone (ESZ) | 0.74 |
| FLX Plus Placebo | 1.04 |
5 reviews available for fluoxetine and Chronic Insomnia
| Article | Year |
|---|---|
Antidepressants for insomnia in adults.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Tricyclic; Fluoxetine; Humans; Mianserin; Parox | 2018 |
Discontinuation symptoms after treatment with serotonin reuptake inhibitors: a literature review.
Topics: 1-Naphthylamine; Adolescent; Adult; Child; Clinical Trials as Topic; Cyclohexanols; Dizziness; Femal | 1997 |
Antidepressant treatment of the depressed patient with insomnia.
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Cyclohexanols; Depressive Disorder; Fluoxetine; Human | 1999 |
Efficacy, adverse events, and treatment discontinuations in fluoxetine clinical studies of major depression: a meta-analysis of the 20-mg/day dose.
Topics: Adult; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Fluoxetine; H | 2000 |
The side effect profile and safety of fluoxetine.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical | 1985 |
33 trials available for fluoxetine and Chronic Insomnia
| Article | Year |
|---|---|
A rest-activity biomarker to predict response to SSRIs in major depressive disorder.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Biomarkers; Depressive Disorder, Major; Female; Fluox | 2015 |
Insomnia severity is an indicator of suicidal ideation during a depression clinical trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Depressive | 2010 |
Treatment of insomnia in depressed insomniacs: effects on health-related quality of life, objective and self-reported sleep, and depression.
Topics: Activities of Daily Living; Affect; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; | 2010 |
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, | 2011 |
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, | 2011 |
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, | 2011 |
A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
Topics: Adult; Anxiety; Azabicyclo Compounds; Depressive Disorder, Major; Double-Blind Method; Drug Therapy, | 2011 |
Dissection of the factors driving the placebo effect in hypnotic treatment of depressed insomniacs.
Topics: Adult; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Depressive Disorder; Drug The | 2011 |
Insomnia moderates outcome of serotonin-selective reuptake inhibitor treatment in depressed youth.
Topics: Adolescent; Age Factors; Antidepressive Agents, Second-Generation; Child; Depressive Disorder, Major | 2012 |
Objective vs. subjective measurements of sleep in depressed insomniacs: first night effect or reverse first night effect?
Topics: Actigraphy; Adult; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Depressive Disord | 2012 |
Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression?
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Anxiety; Clonazepam; Depressi | 2002 |
Citalopram treatment of fluoxetine-intolerant depressed patients.
Topics: Adult; Aged; Citalopram; Depressive Disorder; Drug Tolerance; Female; Fluoxetine; Headache; Humans; | 2003 |
Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Depressive Disord | 2003 |
Reboxetine induces similar sleep-EEG changes like SSRI's in patients with depression.
Topics: Adrenergic Uptake Inhibitors; Adult; Aged; Depressive Disorder, Major; Electroencephalography; Femal | 2004 |
Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
Topics: Adult; Antidepressive Agents, Second-Generation; Azabicyclo Compounds; Depressive Disorder; Double-B | 2006 |
Fluoxetine-mirtazapine interaction may induce restless legs syndrome: report of 3 cases from a clinical trial.
Topics: Adult; Antidepressive Agents; Depressive Disorder, Major; Drug Interactions; Drug Therapy, Combinati | 2006 |
Evaluation of eszopiclone discontinuation after cotherapy with fluoxetine for insomnia with coexisting depression.
Topics: Adult; Azabicyclo Compounds; Comorbidity; Depressive Disorder, Major; Double-Blind Method; Drug Admi | 2007 |
Patterns of improvement in depressive symptoms with fluoxetine treatment.
Topics: Adolescent; Adult; Aged; Appetite; Cognition; Depression; Female; Fluoxetine; Follow-Up Studies; Hum | 1995 |
The effects of fluoxetine on symptoms of insomnia in depressed patients.
Topics: Adolescent; Adult; Depression; Depressive Disorder; Female; Fluoxetine; Humans; Male; Middle Aged; P | 1995 |
Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
Topics: Adolescent; Adult; Aged; Diarrhea; Dose-Response Relationship, Drug; Double-Blind Method; Drug Admin | 1994 |
Trazodone for antidepressant-associated insomnia.
Topics: Adult; Bupropion; Confidence Intervals; Depressive Disorder; Dose-Response Relationship, Drug; Doubl | 1994 |
Safety and tolerability of combined treatment with moclobemide and SSRIs: a systematic study of 50 patients.
Topics: Adult; Benzamides; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Headache; Hum | 1996 |
Should anxiety and insomnia influence antidepressant selection: a randomized comparison of fluoxetine and imipramine.
Topics: Adult; Aged; Anxiety Disorders; Comorbidity; Depressive Disorder; Drug Administration Schedule; Fema | 1998 |
Comparative effects of nefazodone and fluoxetine on sleep in outpatients with major depressive disorder.
Topics: Adult; Ambulatory Care; Antidepressive Agents, Second-Generation; Circadian Rhythm; Comorbidity; Dep | 1998 |
Efficacy and safety of fluoxetine in treating bipolar II major depressive episode.
Topics: Adolescent; Adult; Age of Onset; Aged; Antidepressive Agents, Second-Generation; Bipolar Disorder; C | 1998 |
Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group.
Topics: Adult; Benzamides; Double-Blind Method; Female; Fluoxetine; Headache; Humans; Male; Moclobemide; Mon | 1999 |
Changes in adverse events reported by patients during 6 months of fluoxetine therapy.
Topics: Anxiety; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Fluoxetine; Follow- | 1999 |
Side effects as predictors of drug response in obsessive-compulsive disorder.
Topics: Adolescent; Adult; Anxiety; Clomipramine; Dose-Response Relationship, Drug; Ejaculation; Female; Flu | 1999 |
Acute efficacy of fluoxetine versus sertraline and paroxetine in major depressive disorder including effects of baseline insomnia.
Topics: Acute Disease; Adverse Drug Reaction Reporting Systems; Antidepressive Agents; Depressive Disorder, | 2002 |
Fluoxetine: activating and sedating effects at multiple fixed doses.
Topics: Adult; Akathisia, Drug-Induced; Ambulatory Care; Anxiety; Asthenia; Depressive Disorder; Dose-Respon | 1992 |
Efficacy and safety of morning versus evening fluoxetine administration.
Topics: Adolescent; Adult; Akathisia, Drug-Induced; Circadian Rhythm; Depressive Disorder; Double-Blind Meth | 1991 |
Fluoxetine versus trazodone: efficacy and activating-sedating effects.
Topics: Adult; Akathisia, Drug-Induced; Ambulatory Care; Anxiety; Depressive Disorder; Dizziness; Double-Bli | 1991 |
The evidence for 20mg a day of fluoxetine as the optimal dose in the treatment of depression.
Topics: Adolescent; Adult; Aged; Clinical Trials as Topic; Depressive Disorder; Dose-Response Relationship, | 1988 |
The side effect profile and safety of fluoxetine.
Topics: Adult; Akathisia, Drug-Induced; Antidepressive Agents, Tricyclic; Cardiovascular Diseases; Clinical | 1985 |
A comparison of fluoxetine, imipramine, and placebo in patients with major depressive disorder.
Topics: Adult; Ambulatory Care; Anxiety; Body Weight; Clinical Trials as Topic; Depressive Disorder; Dizzine | 1985 |
A review of multicenter controlled studies of fluoxetine vs. imipramine and placebo in outpatients with major depressive disorder.
Topics: Adolescent; Adult; Aged; Akathisia, Drug-Induced; Ambulatory Care; Anxiety; Clinical Trials as Topic | 1985 |
13 other studies available for fluoxetine and Chronic Insomnia
| Article | Year |
|---|---|
Staying Up at Night: Overlapping Bipolar and Obsessive-Compulsive Disorder Symptoms in an Adolescent with Autism Spectrum Disorder.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Autism Spectrum Disorder | 2016 |
The treatment of comorbid insomnia.
Topics: Adult; Antidepressive Agents, Second-Generation; Depression; Female; Fluoxetine; Follow-Up Studies; | 2009 |
Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment.
Topics: Adult; Alleles; Antidepressive Agents, Second-Generation; Carrier Proteins; Depressive Disorder, Maj | 2003 |
Effect of mirtazapine versus fluoxetine on "sleep quality".
Topics: Antidepressive Agents, Tricyclic; Comorbidity; Depressive Disorder; Dose-Response Relationship, Drug | 2004 |
Unusually prolonged rebound cataplexy after withdrawal of fluoxetine.
Topics: Brain Stem; Cataplexy; Electroencephalography; Electromyography; Female; Fluoxetine; Humans; Middle | 2005 |
Persistent sexual side effects after SSRI discontinuation.
Topics: Adult; Androgens; Anxiety; Bupropion; Cabergoline; Citalopram; Depressive Disorder; Dopamine Agonist | 2006 |
Does trazodone have a role in palliating symptoms?
Topics: Antidepressive Agents, Second-Generation; Depression; Drug Interactions; Fluoxetine; Humans; Neoplas | 2007 |
"I can't sleep at night" an unusual case of insomnia.
Topics: Aged; Anemia, Iron-Deficiency; Blood Transfusion; Colonic Neoplasms; Combined Modality Therapy; Cont | 2005 |
Melatonin as a therapeutic agent in the treatment of sleep disturbance in depression.
Topics: Adult; Depressive Disorder; Drug Therapy, Combination; Female; Fluoxetine; Humans; Melatonin; Sleep | 1997 |
Clarification of the serotonin syndrome.
Topics: Antidepressive Agents, Second-Generation; Arousal; Fluoxetine; Headache; Humans; Serotonin; Sleep In | 1997 |
Trazodone is only slightly faster than fluoxetine in relieving insomnia in adolescents with depressive disorders.
Topics: Adolescent; Antidepressive Agents, Second-Generation; Depressive Disorder; Female; Fluoxetine; Human | 1997 |
Effect of fluoxetine on sleep.
Topics: Adult; Arousal; Bulimia; Depressive Disorder; Female; Fluoxetine; Humans; Sleep Initiation and Maint | 1991 |
Adverse interactions encountered when using trazodone to treat insomnia associated with fluoxetine.
Topics: Adult; Depression; Drug Interactions; Female; Fluoxetine; Humans; Sleep Initiation and Maintenance D | 1990 |